title: Anti-inflammatory action of type I interferons deduced from mice expressing interferon beta.
abstract: Type I interferons (IFN) are widely used for the therapeutic treatment of viral infections, tumor growth and various chronic diseases such as multiple sclerosis. Antagonism between type I IFNs and IFN-gamma has been described in cells of the immune system, in particular in the activation of macrophages. To study the systemic effects of type I IFNs we used transgenic mice carrying a human IFN-beta (hIFN-beta) gene under the control of the rat insulin I promoter. These animals expressed high levels of hIFN-beta in beta-pancreatic cells, and the ability of the macrophages to respond to pro-inflammatory stimuli was analyzed. Transgenic mice exhibited an increased extravasation of cells to the peritoneal cavity after eliciting with thioglycollate broth. The expression of the inducible form of nitric oxide synthase and cyclooxygenase-2, two enzymes involved in inflammation, was impaired in transgenic animals challenged with lipopolysaccharide and IFN-gamma. Analysis of the mechanisms leading to this attenuated inflammatory response showed a decrease in the serum levels of TNF-alpha and an inhibition of the activation of the transcription factor NF-KB in various tissues. These results indicate that systemic administration of IFN-beta might influence the response to pro-inflammatory stimuli, in particular through the antagonism of IFN-gamma signaling.
authors.affiliation: Instituto de Bioquímica (Centro Mixto CSIC-UCM), Facultad de Farmacia, Universidad Complutense, Madrid, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Boscá
authors.forename: O G
authors.initials: OG
authors.lastname: Bodelón
authors.forename: S
authors.initials: S
authors.lastname: Hortelano
authors.forename: A
authors.initials: A
authors.lastname: Casellas
authors.forename: F
authors.initials: F
authors.lastname: Bosch
mesh_terms: D000818:Animals; D051546:Cyclooxygenase 2; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000628:therapy*; D016899:Interferon-beta / Q000235:genetics / Q000276:immunology*; D007371:Interferon-gamma / Q000276:immunology; D007527:Isoenzymes / Q000096:biosynthesis; D008070:Lipopolysaccharides / Q000276:immunology; D008262:Macrophage Activation / Q000276:immunology*; D017737:Macrophages, Peritoneal / Q000276:immunology; D008565:Membrane Proteins; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D016328:NF-kappa B / Q000096:biosynthesis; D019001:Nitric Oxide Synthase / Q000096:biosynthesis; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis; D051381:Rats; D011994:Recombinant Proteins; D019076:Transgenes; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D007527:Isoenzymes; D008070:Lipopolysaccharides; D008565:Membrane Proteins; D016328:NF-kappa B; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D016899:Interferon-beta; D007371:Interferon-gamma; D019001:Nitric Oxide Synthase; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases